On June 28, 2019 Thyas reported that it raised JPY 200 million in Series A1 financing on September 06, with participation from Kyoto University Innovation Capital Co., Ltd., and SMBC Venture Capital Co., Ltd. (Press release, Thyas , JUN 28, 2019, View Source [SID1234629213]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will be used for accelerating the research and development including establishment of cell production methods and preparation of preclinical studies of iPS cell-derived T cell therapy for the treatment of solid cancers.